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Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to eval-
uate the progress in pharmacogenomics education since then, and to put forward further recommenda-
tions. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions
around the world. Results: The majority of the study programs (87%) include pharmacogenomics edu-
cation, which is generally taught as part of the pharmacology curriculum. On average, educators and
teachers have selected appropriate and highly relevant pharmacogenomics biomarkers to include in their
teaching programs. Conclusions: Based on the results, we can conclude that the state of pharmacoge-
nomics education at the surveyed universities has improved substantially since 2005.
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Pharmacogenomics (PGx) aims to determine the influence of genetic and genomic variations on drug responses,
in other words, drug efficacy and toxicity, and it represents an essential step toward personalization of medicine [1].
Since the completion of the Human Genome Project in 2003, the rate of discovery of new PGx biomarkers has
dramatically increased, and one of the healthcare challenges over the last decade has been the implementation of these
genomic biomarkers in clinical practice. Despite the initial enthusiasm with the advent of PGx, its incorporation
into the clinic has been frustratingly slow, and so far it has not met the expectations of the academic community,
physicians and healthcare professionals [2,3]. Many barriers that hinder this process have been identified, such as
the lack of reimbursement of costs of PGx testing [4–8], and the lack of knowledge of healthcare professionals in the
interpretation of PGx tests and the consequent treatment decisions [9]. Also, in many cases, the impact of the results
of PGx testing is limited compared with other sources of variability in patient responses to a drug (i.e., nutrition,
other drugs, drug interactions, alcohol consumption, microbiota, gene–gene interactions, etc) [10,11]. Several studies
have shown that medical professionals agree on the importance of PGx in clinical practice, but that they are reluctant
to use PGx due to inadequate knowledge of the interpretation of PGx tests [12–23].
A first attempt for a call for action for PGx education was made in 2005, with the publication of Gurwitz
et al. [24]. In this article, which was addressed to medical, pharmaceutical and health school Deans of Education, the
authors recommended inclusion of at least 4 h and ideally 8 h, of PGx teaching into the basic medical doctor (MD)
education. For study programs in pharmaceutical, life sciences and public health schools they suggested more
extensive teaching, without specifying the number of hours recommended. To the best of our knowledge, no further
PGx education recommendations that are addressed to Deans of Education have been published. Therefore, our
current survey used the above recommendations as a reference point for a global assessment of the current level of
PGx education.
The aim of this study was to determine the current status of PGx education in medical, pharmaceutical and
health study programs. We evaluated the progress in PGx education over the years since the 2005 recommendations
were published, and on the basis of the survey findings, we make further recommendations.
Methods
Study design
A total of 248 schools of medicine, pharmacy, nursing or health professions were selected from six world continental
regions (Europe, Asia, Africa, North America, South America, and Australia and Oceania). As this study received
no direct funding, it was not possible to include all of the programs worldwide, and therefore only selected schools
were invited. The selection was performed as outlined in the following section. Once an institution had been
selected, contact persons were identified (e.g., Dean, Dean of Education, Chair of Department) and they were sent
e-mails requesting them to complete an on-line questionnaire on PGx education in their institution (Supplementary
Materials 1).
The outcome variables initially analyzed were: PGx subject type; plans for future PGx education implementation;
number of teaching hours for PGx; changes since implementation; use of PGx biomarkers in education; PGx
integration with other fields in the educational process; initial year of PGx implementation; PGx educational
tools; and PGx education in PhD programs. Next, the following comparisons of the outcome variables were
analyzed: between programs, as schools of medicine, pharmacy, nursing, or health professions (including, but not
limited to, laboratory medicine, biochemistry, toxicology and others); between continents, as Europe, Asia, Africa,
North America, South America, and Australia and Oceania; and between member countries in the Organization
for Economic Co-operation and Development (OECD) and non-OECD countries. In addition, the use of PGx
biomarkers in different study programs was compared with the number of PubMed publications and the number
of drugs with prescribing guidelines published by the US FDA for a specific PGx biomarker.
University selection criteria
The participating universities were selected from the Quacquarelli Symonds (QS) World University Rankings
(www.topuniversities.com/). The ranking lists by subject for Medicine and for Pharmacy and Pharmacology were
used, with subsequent filtering for continents and locations (i.e., countries within a specific continent). Separate
lists were made for each of these six continental regions for schools of medicine, pharmacy, nursing or health
professions. The top-ranked university from each country that was included in the MD or Pharmacy top world
ranking was added to the final list. In the case of North America, where there are only three countries, more than
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one top university per country was included. Thus, for North America, ten universities were selected: four each
from the USA and Canada, and two from Mexico. For the continents with <10 universities selected (i.e., Africa,
South America, Australia and Oceania), additional universities were selected from the Webometrics Ranking of
World Universities (www.webometrics.info/en). The ranking lists by region for Africa, South America and Australia
and Oceania were applied for the selection of additional universities from countries that were not on the QSWorld
University Rankings list (as one university per country), and that have one of the programs listed above, according
to their Webometrics ranking. As the eastern European countries were under-represented on the European regional
QS World University Rankings list, an additional ten universities were selected from the Emerging Europe and
Central Asia QS Ranking.
To increase response rates and limit the selection bias of top-ranked universities, additional universities were
selected independent of their ranking, according to membership of the European Society of Pharmacogenomics
and Personalized Therapy (ESPT; i.e., universities whose ESPTmembers were part of ESPT research groups, boards
and national societies). Of note, only 50.8% of the invited ESPT universities came from the top 500 universities
on the QS World University Rankings list.
Questionnaire on pharmacogenomics education in medical doctor, pharmacy & health science
programs
The questionnaire was an updated and extended version of the questionnaire used by Gurwitz et al. in 2005 [24]. It
consisted of 12 questions (as mostly multiple choice) pertaining to PGx education, plus comments and suggestions
sections (Supplementary Materials 1). All of the selected participants were invited by e-mail to participate in the
on-line questionnaire, with its completion from September 8, 2016, to February 21, 2017. The on-line survey was
created using 1 ka (www.1ka.si/d/en), an open-source application for creating, conducting and analyzing online
surveys. Following the initial invitation, three reminders were sent to each participant at 2-week intervals.
PubMed records
The number of PubMed-listed publications for specific PGx biomarkers was obtained from PubMed (www.ncbi.n
lm.nih.gov/pubmed/) on January 18, 2019, using the advanced search mode with the terms ‘pharmacogenetics’ or
‘pharmacogenomics’ together with the names of the relevant human genes from the HUGO Gene Nomenclature
Committee.
The number of drugs with FDA drug labels for specific PGx biomarkers was obtained from The Pharmacoge-
nomics Knowledgebase (PharmGKB; www.pharmgkb.org/; last accessed, January 18, 2019) using the names of
the genes from the HUGO Gene Nomenclature Committee as the search term. The prescribing information was
found under the tab Drug labels.
Statistical analysis
Descriptive statistics were used to present the global results. For comparisons between two groups, Fisher exact
(for categorical data) and Mann–Whitney U (for non-Gaussian continuous or ordinal data) tests were used.
For comparisons between three or more groups, Fisher exact (for categorical data) and Kruskal–Wallis (for non-
Gaussian continuous or ordinal data) tests were used. For testing correlations between the use of PGx biomarkers
and the number of PubMed publications or the number of drugs with prescribing guidelines for a specific PGx
biomarker, nonparametric Spearman correlations were used. All of these tests were carried out using the SPSS
statistical program (version 24; IBM, NY, USA). For all of the statistical tests, differences with p values ≤ 0.05 were
considered significant.
Results & discussion
Description of the study cohort
Of the 248 invited institutions, 69 responded, which provided an overall response rate of 27.8%. There were
substantial differences in the response rates between the different world regions, with the highest in European
countries (34.7%), and the lowest in South America (9.0%). Detailed response rate data and cohort characteristics
are listed in Tables 1 and 2, respectively. The questionnaire, as well as the emails to contact persons (and reminders),
were written in English; moreover, ESPT members were included in the survey (see Methods). These factors may
in part explain the higher response rate from Europe.
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Table 1. Response rates by location of institution (overall and by continent).
Continent Number of invited institutions Responders (N) Response rate (%)
Overall 248 69 27.8
Europe 101 35 34.7
Asia 47 10 21.3
Africa 22 7 31.8
North America 27 7 25.9
South America 22 2 9.0
Australia and Oceania 29 8 27.6
In some cases, the response rates by program can be higher, as some institutions answered the survey for several different programs.
Table 2. Description of the study cohorts.
Characteristic Subgroup Number of programs Proportion (%)
Program category All 97 100.0
MD 44 45.4
Pharmacy and pharmacology 34 35.1
Nursing 3 3.1
Graduate school in a faculty of
medicine or life sciences
13 13.4
Other† 3 3.1
Continent All 82 100.0
Europe 38 46.3
Asia 15 18.3
Africa 7 8.5
North America 8 9.8
South America 3 3.7
Australia and Oceania 11 13.4
OECD country All 82 100.0
Yes 49 59.8
No 33 40.2
The total number of programs varies between the categories as in some cases the survey was not completed by the participants, and thus specific categories included lower numbers of
answers.
†Biochemistry (1), Laboratory medicine (1), School of Medicine and Dentistry (1).
MD: Medical doctor; OECD: Organization for Economic Co-operation and Development.
Prevalence, form & future implementation of pharmacogenomics education
Among the study programs included, 13.4% reported no PGx education (Figure 1A).
In about half of the programs that included PGx education, PGx was taught as part of the pharmacology
curricula, followed by its teaching as independent elective (19.6%) and mandatory (10.3%) subjects (Figure 1A).
This finding is in line with the 2005 recommendation for medical, pharmacy and health schools to incorporate
PGx as an integral part of their core pharmacology curricula [24]. Significantly fewer programs in graduate schools
reported PGx education as a part of pharmacology (15.4%) compared with MD (59.1%), pharmacy (50.0%) and
nursing (66.7%) programs (Fisher’s exact test; p = 0.049).
The frequencies of study programs that included PGx in their pharmacology curricula were also compared
between continents: PGx was reported as a part of the pharmacology curricula by 55.3% of the programs from
Europe, 53.3% from Asia, 85.7% from Africa, 12.5% from North America and 36.4% from Australia and Oceania
(Fisher exact p = 0.075). The distribution of the programs with PGx as an independent mandatory or elective
subject did not differ between the subgroups. Among the responders, 9.3% indicated that PGx was included in
other subjects not specifically listed in Figure 1A. The subgroup analysis showed that PGx as a part of alternative
subjects was reported by 18.4% of the responders fromOECD countries, and by none from non-OECD countries.
These data are in line with majority of other published studies on PGx education in medical and pharmaceutical
programs. Studies by Green et al. and Higgs et al. reported that in North America and Britain, 82 and 84%,
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Figure 1. Pharmacogenomics education integration and future implementation of the responding institutions. (A)
By subject. Other subjects with pharmacogenomics topics not shown include: pharmacokinetics (three responders),
oncology and psychiatry (two responders each), and drug development, molecular biology, biopharmacy, homeostasis
and organ-system study modules (one responder each). (B) Plans for the future implementation of
pharmacogenomics.
PGx: Pharmacogenomics.
respectively, of participating medical schools had PGx incorporated into their programs [25,26]. Similar to the
present data, PGx was seldom taught as a standalone course, and it was most often part of the pharmacology
course [25,26]. In the more recent study by Murphy et al., among responders from US schools and colleges of
pharmacy, 89% reported PGx as included in their PharmD curriculum, and 21% where it was a standalone course,
with others including it as a part of other mandatory or elective courses [27]. A study by Pisanu et al. investigated the
state of PGx education in southeastern Europe (i.e., Greece, Italy, Cyprus, Malta, Turkey, Albania, Bulgaria, Serbia,
Montenegro, Bosnia and Herzegovina, Croatia). They reported that PGx teaching varied considerably between
countries, and even between universities within the same country. In certain countries (i.e., Cyprus, Malta) PGx
was not included in the curricula of any of their participating universities, while in others (i.e., Greece, Italy), it
was taught in all of the programs studied, often as an independent course. In other southeast European universities
included in their study, the incorporation of PGx into the health care curricula was variable, and taught mostly as
a part of other courses that were offered, rather than as a standalone course [20].
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Number of teaching hours for pharmacogenomics, & changes since the implementation of
pharmacogenomics education
Most programs offer 1–2 h of PGx teaching, followed by 3–4 h and >10 h in equal proportions (Figure 2A). 63%
of the programs offer at least the minimum recommended number of hours, as recommended by the 2005 ISP
recommendations (i.e., 3–4 h) [24], where more pharmacy (75.9%) and graduate school (80.0%) programs reached
this 3-4 h minimum than for MD (48.5%) and nursing (0.0%) programs (Figure 2B).
Other studies have also reported low numbers of hours of PGx coursework in medical school curricula, with
only 21% of British medical schools [26] and 28% of medical schools in the USA and Canada [25] offering ≥4 h of
PGx teaching. In the same two studies, the majority of the schools considered the offered amount of PGx teaching
to be sufficient, and only 29% of North American medical schools planned to increase the number of hours for
PGx [25,26]. Our survey shows that in the USA, pharmacy schools have integrated PGx into their curricula to a
greater extent compared with medical schools. In line with this, Murphy et al. [27]. reported that more than half of
their participating institutions reported having ≥10 h of PGx coursework included in their pharmacy programs,
and 46% of colleges planned to increase the number of hours of coursework dedicated to PGx instruction.
Use of pharmacogenomics biomarkers in education
The genomic markers used in PGx education and their frequency of use as reported by the survey responders, as
well as their frequency of usage are illustrated in Figure 3A. The most frequently taught PGx biomarkers were the
three CYP genes (CYP2D6, CYP2C19, CYP2C9), which were all used at frequencies > 80%; this is in line with
the 2005 ISP recommendations [24]. These were followed by VKORC1, TPMT, UGT1A1 and the ABC transporter
family genes, with frequencies of use from 50 to 70% (Figure 3A). The use of biomarkers correlated significantly
with their level of evidence according to PharmGKB, with those with higher levels of evidence used more frequently
(Kruskal–Wallis p = 0.001) (Figure 3A). Of note, the PharmGKB clinical annotation levels of evidence at least
partly correspond to the Clinical Pharmacogenetics Implementation Consortium levels (CPIC A, B, C, D). CPIC
assigns these CPIC levels to genes/ drugs with PharmGKB clinical cnnotation cevels of cvidence of 1A, 1B, 2A and
2B, or a PharmGKB PGx level for FDA-approved drug labels of ‘actionable PGx,’ ‘genetic testing recommended,’
or ‘genetic testing required,’ or based on nomination to CPIC for consideration [28].
Overall, the median number of PGx biomarkers used per study program was seven (minimum–maximum,
1–11). Study programs from Europe included the highest median number of PGx biomarkers, followed by North
America, Asia, Africa and Australia and Oceania (Kruskal–Wallis p = 0.033; Figure 3B).
Next, we investigated the correlation between PGx biomarker use and the number of PubMed publications
relating to the specific marker (Figure 3C), and the number of drugs with an FDA drug label for a specific
biomarker (Figure 3D). As shown in Figure 3A, the markers with CPIC A level of evidence (which corresponds to
PharmGKB 1A) were used more frequently than those markers with lower levels of evidence. These results indicate
that on average, educators and teachers select both appropriate and highly relevant PGx biomarkers to include in
their teaching programs.
Pharmacogenomics integration with other fields of educational practice
In the present survey, 40% of responders reported integration of PGx with other -omics (Figure 4A). We can
therefore conclude that a minority of programs integrates PGx with other scientific fields, and thus in most study
programs personalized medicine teaching is limited only to the genomic level.
The situation is more encouraging considering the use of companion diagnostics and case studies in PGx
education (Figure 4B & C). This is in line with the 2005 ISP recommendations to include case studies in PGx
teaching materials [24].
The implementation of PGx education
On average, most programs started with PGx courses in 2007 (95% confidence interval, 2006–2009; min–
max, 1995–2017), and programs from OECD countries started significantly earlier than those from non-OECD
countries (mean, 2006 [min–max, 1995–2017] vs 2009 [min–max, 2000–2014]; t-test p = 0.035). Obviously,
knowledge about the human genome sequence is crucial for the development of PGx markers, and indeed, 82.1%
of the programs started to implement PGx topics after the completion of the Human Genome Project. Considering
the clinical training associated with the study programs, the establishment of PharmGKB and CPIC might have
been even more important time points for evaluation. PharmGKBwas launched in 2000, and CPIC was established
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Figure 3. Use of pharmacogenomics biomarkers in education at the responding institutions. (A) Proportions of study programs teaching
about each of the listed pharmacogenomics (PGx) biomarkers. The PGx biomarker PharmGKB levels of evidence are indicated as:
†1A; ‡1B; §2A; #2B; ¶3.
The 1A level of evidence corresponds to Clinical Pharmacogenetics Implementation Consortium A, except in the case of the ABC
transporters, which are assigned a Clinical Pharmacogenetics Implementation Consortium A/B level of evidence. High level of evidence
1A markers were used significantly more frequently than lower level evidence markers (Kruskal–Wallis, p = 0.001). (B) Numbers of PGx
biomarkers used per program, giving an overall median (min–max) of 7 (1–11). This median is significantly higher in Europe, Asia and
North America compared with Africa and Australia and Oceania (Kruskal–Wallis, p = 0.033). (C, D) Relationships between PGx marker use
in education and PubMed publications (C) and US FDA drug labels (D). Significant correlations are seen for number of PubMed
publications per marker (C; Spearman’s rho, 0.643, p = 0.001) and number of FDA drug labels per PGx marker (D; Spearman’s rho, 0.635,
p = 0.001).
PGx: Pharmacogenomics.
in 2009. Only 6.0% of the study programs surveyed started implementation of PGx topics prior to the release of
PharmGKB, while 56.7% were already teaching PGx at the time of the establishment of CPIC.
PGx educational tools
The most frequently used educational tools for teaching PGx are original research papers (70.8%), followed by
internet data bases (48.6%) and textbooks (41.7%) (Figure 5A).
This situation has not changed much since the beginnings of PGx education, except for the wider availability
of PGx textbooks [29]. Our findings are expected, given that research papers are available on-line and provide up-
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Figure 4. Pharmacogenomics integration with other fields in the educational process at the responding institutions.
(A) Integration of PGx education with other ‘-omics’ (OMICs), where the majority show little integration. The most
commonly are epigenomics and bioinformatics. (B) Use of companion diagnostics in PGx education, where 74% of the
study programs were positive. (C) Use of case studies in PGx education, where 71% of the study programs were
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PGx: Pharmacogenomics.
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Figure 5. Use of pharmacogenomics education tools at the responding institutions. (A) Type of teaching sources used. (B) Most
frequently reported internet databases used. (C) Most frequently reported textbooks used. (D) Use of original scientific papers, which was
most frequent in pharmacy and least frequent in nursing study programs (Fisher’s exact test; p = 0.043).
†PhD theses, simulators and mobile apps.
‡Each reported once (see Supplementary Table 1).
§Each reported once (see Supplementary Table 2).
EMA: European Medical Agency; MD: Medical doctor; PGx: Pharmacogenomics.
to-date information, compared with textbooks. Moreover, according to a Directive of the European Commission
of Open-Access Publishing, increasing numbers of journals offer open access, which is likely to lead to even higher
use of original research papers in higher education. The use of original research papers for PGx education that was
evident from our global survey is again in line with the 2005 recommendations [24].
Internet databases were also very popular for PGx education, and equally so among all of the subgroups of
responders. This is probably because they typically have open access, while many original research papers are still
kept behind pay walls and are not accessible to all universities. This use of web resources in PGx education is
also in line with the 2005 recommendations [24]. By far the most frequently used website for PGx education was
PharmGKB [30], which was reported by 60.0% of all of the internet database users (Figure 5B; Supplementary
Table 1).
The majority of the textbooks used by our survey responders were in the field of pharmacology and toxicology,
and in one instance biochemistry (Supplementary Table 2).
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Table 3. Recommendations checklist from 2005, with the results realization and the future recommendations from the
present study.
Recommendation in 2005 Realization in studied universities Further recommendations
Incorporate the teaching of PGx into the core
pharmacology curricula of medical, pharmaceutical
and health schools
Yes (Figure 1A) Implement PGx as a stand-alone elective or mandatory
subject in pharmacy and health schools, when possible
(i.e., new or redesigned study programs)
Incorporation of PGx into the basic education of
physicians, pharmacists and nurses
Yes (Figure 1A) None
At least 4 h of PGx teaching per program Partly (Figures 2A, B) Reach 4 h minimum for MD and nursing programs
Include relevant markers in PGx education Partly (Figure 3) Increase use of non-CYP level 1A PGx markers
More extensive PGx teaching in pharmaceutical, life
science and health schools
Yes (Figure 2B) None
PGx as a part of continuing medical education and
oncology
Not assessed NA
PGx educational material should be updated regularly Yes (Figure 4A) None
Dedicate a separate chapter to PGx in pharmacology
textbooks
Yes (Figure 5C, Supplementary Table S2) Increase the number of textbooks dedicated specifically
to PGx
Use review articles, web resources and case studies as
PGx teaching materials
Yes (Figures 4C & 5A) None
Creation of open-access comprehensive web-based
tutorials (on-line lectures, presentations and
manuscripts)
Not assessed NA
Better PGx education for healthcare professionals and
patients
Not assessed NA
MD: Medical doctor; NA: Not applicable; PGx: Pharmacogenomics.
Pharmacogenomics education in PhD programs
Finally, the responders were asked whether they offer PGx education to their PhD students; these findings are
presented in Figure 6. Of 30 PhD programs that offered PGx education, 43.3% were MD, 30.0% pharmacy,
23.3% graduate schools in faculties of medicine or life sciences, and 3.3% laboratory medicine. These data are
similar to those of Murphy et al. [27], who reported that 39% of their participating pharmacy schools and colleges
teach PGx at the PhD level, and 10% offer PhD degrees focused on PGx. In a study by Pisanu et al. in southeastern
Europe, PGx was taught in 23% of postgraduate programs (PhD, MSc, medical specialties studies), in 12.5% as a
standalone course and in 87.5% as a part of other modules or courses [20].
Limitations of this study
The major limitation of this study is that it had a relatively low response rate, which might have led to inaccurate
representation of the global picture. However, the low response rate does not automatically imply low validity of
the study, it simply indicates potentially greater bias [31]. For example, evaluations of national surveys by Holbrook
et al. [32] with response rates ranging from 5 to 54% have concluded that studies with a much lower response
rates were often only marginally less accurate than those with much higher response rates. More recently, Mealing
et al. [33]. considered relative risk estimates from two studies drawn from the same population in an Australian cohort
study, and showed that despite the very different response rates (18 vs 60%) and different data collection methods
(postal vs phone collection), the estimates of exposure and outcome relationships were particularly consistent where
the same questions were asked. The most important indicator of the validity of a study are the differences between
responders and nonresponders [31]. Unfortunately, in this case, these differences, and consequently the study validity,
could not be assessed due to the nature of the study design.
Another concern is the low absolute number of responding institutions per continent, and in particular for South
America, where only two universities responded to the survey. Thus, the data obtained for South American schools
are less likely to be representative, and therefore they were not included in the statistical analysis.
Surveying primarily top-ranked universities might introduce additional bias. Finally, the additional selection of
universities from the ranks of the ESPT members (10 universities) might have led to the over-representation of
European countries.
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Figure 6. Inclusion of pharmacogenomics education in PhD programs at the responding institutions. (A) PGx
education included in PhD program. (B) Number of PGx teaching hours per PhD program. (C) PGx education in PhD
programs by continent. None of the responders from Africa and Australia and Oceania include PGx topics in their PhD
programs, with highest inclusion seen for North America (Fisher’s exact test; p = 0.127).
†Median (min–max) number of PGx teaching hours: 27.5 h (15–100 h).
PGx: Pharmacogenomics.
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Box 1. Further recommendations.
Overall, the state of pharmacogenomics (PGx) education has substantially improved since the publication of the first
consensus paper [24]. However, after reviewing all of the goals that were set, we find that there is still room for
improvement (Table 3):
• Although the majority of medical doctors (MD), pharmacy, nursing and public health school study programs offer
PGx education in some form, it is mostly as a part of pharmacology and other topics. It would be unrealistic to
recommend the implementation of PGx education as either an elective or a mandatory topic in most MD and
nursing school programs. However, in pharmacy schools, an effort should be made to include PGx education as a
stand-alone topic.
• Most study programs offer the minimum recommended number of hours of PGx eduaction. However, < 50% of
MD and nursing programs responding to our survey reached this goal. Thus, further efforts are needed to
increase the number of PGx hours, with particular focus on MD and nursing programs.
• The most encouraging finding of this survey is that educators have included relevant and clinically promising PGx
markers in their teaching curricula. However, while the use of the CYP gene family markers is high, some 1A level
of evidence markers (including some already widely applied in clinical practice) are being neglected. Thus,
teachers should strive to increase the number of PGx markers taught, with a focus on those with high levels of
evidence.
In addition to recommendations pertaining to the 2005 consensus paper [24], we have identified several other
points that are in need of improvement:
• Programs with no PGx curricula were more common in non-Organization for Economic Co-operation and
Development (OECD) countries, compared with OECD countries. We recommend the inclusion of PGx education
in E-learning programs for low-income countries [30] .
• The number of PGx markers taught per program was significantly lower for Africa and Australia and Oceania,
compared with other continents. Therefore, we recommend that educators strive to increase the number of PGx
markers in their curricula to at least eight per program (i.e., median for Europe).
• A minority of programs have integrated PGx with other scientific fields, and thus the teaching is limited to only
the genomic level. We recommend the integration of PGx curricula with other ‘-omics’ (especially with
epigenomics and metabolomics), and most importantly with bioinformatics (i.e., use of bioinformatics tools).
• Most of the universities surveyed do not offer PGx education for PhD students, and in particular, none of the
responders from Africa and Australia and Oceania. Conversely, >50% of the responders from North America
implement PGx education in their biomedical PhD program. We strongly recommend the implementation of PGx
education in particular for biomedical PhD programs globally, as students in these programs are the most likely
to be employed by biomedical research institutions, private sector pharmaceutical and diagnostic companies, and
the rapidly evolving E-health sector.
Conclusion
The majority of the recommendations that arose from the 2005 call for action [24] that were assessed in the present
survey are shown to have been addressed (Table 3). In short, the majority of the surveyed study programs include
PGx education, which is mostly taught as part of a pharmacology curriculum. However, a minority of programs
integrate PGx with other scientific fields, and thus in most study programs, personalized medicine teaching is
limited only to the genomic level. Further recommendations based on our survey findings are given in Box 1.
Future studies in the field of PGx education should also address PGx as part of the continuing education of
healthcare professionals, and in addition, they must promote the dissemination of PGx knowledge in lay terms,
for the general public. While these topics were not covered by our current survey, they will also be crucial for the
success of implementing PGx tests for wider clinical use.
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Summary points
• The majority of the study programs (87%) include pharmacogenomics (PGx) education, which is mostly taught as
part of a pharmacology curriculum.
• Sixty-three percent of programs offer at least the minimum recommended number of hours of PGx teaching
(i.e., 3–4 h), as recommended by the 2005 consensus article.
• The median number of PGx biomarkers used per study program was seven (1–11).
• The most frequently taught PGx biomarkers were three CYP genes (CYP2D6, CYP2C19, CYP2C9), all of which were
used at frequencies >80%, which is in line with the 2005 ISP recommendations.
• The use of biomarkers in PGx education positively correlated with their level of evidence according to PharmGKB,
the number of PubMed publications and the US FDA drug labels.
• A minority of programs integrate PGx into other scientific fields, and thus in most study programs personalized
medicine teaching is limited to only the genomic level.
• The most frequently used educational tools for teaching PGx are original research papers (71%), followed by
internet data bases (49%) and textbooks (41%).
• Only 30% of study programs offer PGx as a part of the PhD curriculum.
• Based on these results, we can conclude that the state of PGx education has substantially improved since 2005,
although there remains room for improvement.
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